Shots:

• Following a joint clinical research agreement between Roche and Exelixis and in conjunction with certain rights granted in Japan- Chugai and Takeda will study Tecentriq (atezolizumab) and Cabometyx (cabozantinib) as a combination therapy in Japan
• The three global P- III CONTACT studies are ongoing to investigate the combination of atezolizumab and cabozantinib as a potential new treatment option in multiple tumor types- and Chugai and Takeda are planning to join in supporting P-III studies in Japan
• Tecentriq is a mAb targeting PD-L1- acts by blocking is its interactions with both PD-1 and B7.1 receptor. Cabometyx is approved for advanced RCC and for HCC prior treated with sorafenib in the US

Click here ­to­ read full press release/ article 

 Ref: Chugai | Image: Takeda